FIELD: pharmaceuticals.
SUBSTANCE: invention relates to double-action supramolecular complexes (compounds), which have the effect of blocking angiotensin II (AT1), neprilysin inhibitors (NEPi) and represent the compound (EXP3174·AHU377)·1,5Ca·2H2O and (EXP3174·AHU377)·1,5Ca·2,5H2O.
EFFECT: disclosed are compounds of a metabolite of an angiotensin II receptor antagonist and an NEPi inhibitor, and methods of producing said compounds.
10 cl, 7 tbl, 9 ex, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| VERSIONS OF USING COMPLEX OF ANGIOTENSIN II RECEPTOR ANTAGONIST METABOLITE AND NEP INHIBITOR IN TREATING HEART FAILURE | 2020 |
|
RU2820827C1 |
| GALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2017 |
|
RU2773029C2 |
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSINE RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2459809C2 |
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSIN RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2503668C2 |
| SUBSTITUTED DERIVATIVES OF BISPHENYL ESTER OF BUTYRIC ACID AS NEP INHIBITORS | 2019 |
|
RU2784522C2 |
| NEP INHIBITORS FOR TREATMENT OF DISEASES CHARACTERIZED BY ATRIAL ENLARGEMENT OR REMODELING | 2018 |
|
RU2809222C2 |
| NEP INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ATRIAL ENLARGEMENT OR REMODELING | 2013 |
|
RU2667643C2 |
| DOUBLE-ACTION PHARMACEUTICAL COMPOSITIONS OF SUBMOLECULAR STRUCTURE OF ANGIOTENSIN RECEPTOR BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR | 2008 |
|
RU2493844C2 |
| CRYSTALLINE FORMS OF ALISKIREN HEMIFUMARATE | 2007 |
|
RU2466982C2 |
| TREATMENT OF HYPERTENSION AND/OR PREVENTION AND TREATMENT OF HEART FAILURE IN MAMMAL, RECEIVING ANTICOAGULANT THERAPY | 2011 |
|
RU2564941C2 |
